Belgium Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per thousand citizens, compared to the EU average of five per thousand citizens) and the second-highest number of doctor consultations per…
USA Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s largest – but perhaps most complex – pharmaceutical market. While the sheer dominance of the US market – the largest in the world, accounting for around…
Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
USA With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the novel coronavirus. However, even as great strides have been made on that front, companies have to continue delivering their existing…
Opinion Jessica Scott, Takeda’s head of R&D patient engagement, highlights how a better understanding of the value of patient engagement across the healthcare stakeholder spectrum will drive better health outcomes and why keeping an open and curious mindset is crucial in this endeavour. By incorporating Patient Engagement (PE) into the…
Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while enabling us to maintain a culture of innovation and growth. Are social distancing requirements causing the life science industry to return to an inward-looking culture of secrecy?…
Sanofi Sanofi’s inflammation drug Dupixent® is driving a substantial percentage of the firm’s sales in 2020, reaching USD 1.92 billion in the first half of the year, with a reported growth of 94 percent. Sanofi Genzyme Executive VP Bill Sibold recently spoke exclusively to PharmaBoardroom about the drug’s success. Dupixent®…
Japan Yoji Yuki, CEO of Japanese regenerative medicine company UniBio, recalls the roots behind the venture and its plant-based technology. He also sets out his ambitions to expand and develop greater manufacturing capabilities in order to meet UniBio’s future ambitions. What is most important to stress is that there are…
Novartis Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company’s culture of ‘curious, inspired, and unbossed,’ how Novartis differentiates itself in a highly competitive oncology landscape, learnings from recent product launches, and how Novartis is working to make its CAR-T therapy more accessible…
Precision Medicine With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region must be addressed effectively, quickly and comprehensively. Who better to accomplish that than the Asian companies on the ground, closest…
Sanofi With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on June 15th 2020. Under the watch of CEO Paul Hudson, appointed at the end of 2019, Sanofi has initiated…
Data New approaches to pharma sales: Marrying data analytics with the art of personal engagement The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume,…
See our Cookie Privacy Policy Here